Future science OA · 2025
Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pianko Matthew J, Gupta-Werner Niodita, Emond Bruno, Lefebvre Patrick, Lafeuille Marie-Hélène, Cortoos Annelore, Kaila Shuchita
Аннотация
AIMS: To identify predictors for initiation of frontline doublet versus triplet therapy for transplant-ineligible newly diagnosed multiple myeloma.
MATERIALS AND METHODS: Using Flatiron Health data, a random forest model was used to identify baseline predictors of frontline doublet or triplet use.
RESULTS: The random forest model had good predictive power, with 74% probability of successfully predicting the regimen received (doublets or triplets) for a given patient. Regression analyses found that patients treated with doublets were more likely to be older (age ≥80 versus <60 years: odds ratio [OR] = 0.15, P < 0.001) and frail (frail versus fit: OR = 0.73, P = 0.023). Predictors of triplet regimen use included Black race (Black versus white: OR = 1.31, P = 0.025), urban state (urban versus rural: OR = 1.38, P = 0.042), ≥1 form of trisomy (OR = 1.39, P < 0.001), del(17/17p) (OR = 1.87, P < 0.001), detectable M protein (OR = 1.33, P < 0.001), higher disease stage per International Staging System (stage 2 versus 1: OR = 1.42, P = 0.001; stage 3 versus 1: OR = 1.35, P = 0.005), and ≥1 diagnosis for musculoskeletal and connective tissue diseases (OR = 1.45, P = 0.002). Triplet regimen use increased in recent years.
CONCLUSIONS: While frontline triplet therapies have shown improved efficacy over doublets with tolerable safety, doublet use remains in older and frail patients, creating an opportunity to improve outcomes in this particular patient population.
MATERIALS AND METHODS: Using Flatiron Health data, a random forest model was used to identify baseline predictors of frontline doublet or triplet use.
RESULTS: The random forest model had good predictive power, with 74% probability of successfully predicting the regimen received (doublets or triplets) for a given patient. Regression analyses found that patients treated with doublets were more likely to be older (age ≥80 versus <60 years: odds ratio [OR] = 0.15, P < 0.001) and frail (frail versus fit: OR = 0.73, P = 0.023). Predictors of triplet regimen use included Black race (Black versus white: OR = 1.31, P = 0.025), urban state (urban versus rural: OR = 1.38, P = 0.042), ≥1 form of trisomy (OR = 1.39, P < 0.001), del(17/17p) (OR = 1.87, P < 0.001), detectable M protein (OR = 1.33, P < 0.001), higher disease stage per International Staging System (stage 2 versus 1: OR = 1.42, P = 0.001; stage 3 versus 1: OR = 1.35, P = 0.005), and ≥1 diagnosis for musculoskeletal and connective tissue diseases (OR = 1.45, P = 0.002). Triplet regimen use increased in recent years.
CONCLUSIONS: While frontline triplet therapies have shown improved efficacy over doublets with tolerable safety, doublet use remains in older and frail patients, creating an opportunity to improve outcomes in this particular patient population.